Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): Current status

Cytotherapy

Volumn 4, Issue 3, 2002, Pages 241-251

  Anderlini, Paolo ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Allogeneic stem cell transplantation; Autologous stem cell transplantation; Hematopoietic stem cell transplantation; Hodgkin's disease; Reduced intensity conditioning

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; RITUXIMAB;

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; FEASIBILITY STUDY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE TRANSFUSION; MAINTENANCE THERAPY; MORBIDITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035995204     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532402320219754     Document Type: Article

References (61)

1. Hodgkin's disease
2. Problems in Hodgkin's disease management
3. Controversies in the management of early-stage Hodgkin's disease
4. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD
5. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988
6. Autologous hematopoietic stem cell transplantation in Hodgkin's disease
7. Role of high-dose therapy and stem cell transplantation in the management of Hodgkin's disease
8. High-dose therapy for Hodgkin's disease
9. Autologous transplantation for Hodgkin's disease: Coming of age?
10. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial
11. High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): Final results of a randomized GHSG and EBMT trial
12. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry
13. High-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy
14. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation
15. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group
16. Comparison of high-dose therapy and autologous stem cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study
17. Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR)
18. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT
19. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry
20. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy
21. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy
22. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: A single-center 8-year study of 155 patients
23. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante autologo de Medula Osea Spanish Cooperative Group
24. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors
25. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices
26. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease
27. ABMT in recurrent or refractory HD: Long term results
28. High-dose chemotherapy followed by autologous stem cell rescue in Hodgkin's disease: Long-term follow-up in 128 patients
29. A prognostic score for advanced Hodgkin's disease
30. The Hodgkin's disease Prognostic Index predicts outcome of autologous stem cell transplantation (ASCT)
31. Peripheral blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphomas: A new matched-pair analysis of the European Group for Blood and Marrow Transplantation
32. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy
33. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk, advanced-stage Hodgkin's disease during first partial or complete remission
34. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: Retrospective analysis of 158 cases from the French Registry
35. Early high-dose therapy to consolidate patients with high-risk Hodgkin's disease in first complete remission? Results of an EBMT/GHSG matched pair analysis
36. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: A retrospective study from the Spanish GEL-TAMO Cooperative Group
37. EBMT/ANZLG/Intergroup HD01 trial: High-dose therapy and autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: Analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol
38. Autotransplantation for relapsed or refractory Hodgkin's disease: Long-term follow-up and analysis of prognostic factors
39. Radiation therapy as a component of high-dose salvage strategies for Hodgkin's disease
40. Secondary neoplasms after Hodgkin's disease
41. Second cancer risk following Hodgkin's disease: A 20-year follow-up study
42. Risk of second malignancy after Hodgkin's disease in a collaborative British Cohort: The relation to age at treatment
43. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease
44. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
45. Multicenter evaluation of the high-dose sequential (HDS) chemotherapy regimen as salvage treatment for refractory/relapsed Hodgkin's disease
46. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study
47. Increased treatment failure in patients with CD20 positive classic Hodgkin's disease (HD)
48. MAb therapy: The use of antiCD20 abs. Therapeutic uses of MAbs directed against CD20
49. α-Interferon treatment of Hodgkin's disease
50. Maintenance therapy with interferon alfa 2b in Hodgkin's disease
51. Cytotoxic T-lymphocyte therapy for relapsed EBV+ HD
52. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease
53. Allogeneic, syngeneic and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience
54. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease
55. Long-term follow-up of bone marrow transplantation for Hodgkin's disease: Evidence for a graft-versus-tumor effect
56. Allogeneic hematopoietic transplantation as adoptive immunotherapy: Induction of graft-vs.-malignancy as primary therapy
57. Allogeneic hematopoietic stem cell transplantation after immunosuppressive but non-myeloablative conditioning: 'Miniallografts' are no small matter
58. Higher than expected transplant-related mortality and relapse following non-myeloablative stem cell transplantation for lymphoma adversely effects progression-free survival
59. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation
60. Autografting followed by non-myeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma
61. Adoptive immunotherapy for treatment of Hodgkin's disease: Proof of principle